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Introduction: A novel fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) is currently undergo-
ing clinical investigations.
Objective: This study was conducted to examine the biodistribution of rVIIa-FP in comparison to recombinant
factor VIIa (rFVIIa).
Materials andMethods: [3H]-rVIIa-FP (10mg kg−1) or [3H]-rFVIIa (1.6mg kg−1) were administered intravenously
to rats, followed by quantitative whole-body and knee joint autoradiography for 24 ([3H]-rFVIIa) or 240 ([3H]-
rVIIa-FP) hours post-dose. Pharmacokinetic and excretion balance analyses were performed.
Results: In contrast to [3H]-albumin, the tissue distributions of [3H]-rVIIa-FP and [3H]-rFVIIa were similar. Within
the knee, both were rapidly present within synovial and mineralized regions. Importantly, rVIIa-FP- and
albumin-derived radioactivity were detectable up to 72–120 hours, whereas [3H]-rFVIIa signals were already
close to detection limits at 24 hours. The longest rVIIa-FP retention timeswere observed in bonemarrow and end-
osteum, in which the retention times were up to 5 times longer for rVIIa-FP compared with rFVIIa. Up to 8 hours
post-dose, 100% of radioactivity was assigned to unchanged [3H]-rVIIa-FP. Elimination of both proteins occurred
primarily via the urine.
Conclusions: The data suggest that the FVIIa moiety is directing rVIIa-FP’s tissue distribution while the albumin
moiety is responsible for the prolonged tissue retention. Importantly, rVIIa-FP is highly concentrated and retained
over a long period in the growth plate of the knee joint− a vulnerable site in haemophilia patients. Overall, these
improved tissue distribution characteristics of rVIIa-FP may enhance compliance and allow a more convenient
dosing frequency.
© 2014 Elsevier Ltd. All rights reserved. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Activated factor VII (FVIIa) is an important therapeutic option for
haemophilia patients with inhibitors− up to 52% of previously treated
patients with severe haemophilia A develop inhibitors to factor VIII, and
up to 5% of patients with haemophilia B develop inhibitors to factor IX
[1,2]. In these patients, recombinant FVIIa (rFVIIa) is used as a bypassing
agent to achieve coagulation and cessation of bleeding in case immune
tolerance induction (ITI) is not successful. However, theuse of rFVIIa has
been limited, to date, due to its rapid elimination from the circulation.tivated factor VII; HPLC, high-
ce induction; LMW, low molec-
BA, quantitative whole-body
FP, recombinant fusion protein
von-Behring Strasse 76, 35041
21 39 4663.
g).
an open access article under the CCWith a terminal half-life of only 2.5 hours in humans [3], frequent injec-
tions of rFVIIa are required to manage haemophilia, limiting its
applicability as a long-term treatment option for prophylaxis [4].
The recombinant fusion protein linking coagulation factor VIIa with
albumin, rVIIa-FP (CSL689), has been designed to extend the half-life of
this coagulation factor [4,5]. Pre-clinical studies to date have shown that
rVIIa-FP provides a half-life extension of at least 4-fold that of rFVIIa, an
increased in vivo recovery of approximately 2-fold over rFVIIa and an
area under the curve (AUC) that is approximately 10-fold higher [6];
thus, affording amuch longer opportunity for procoagulant activity. Ini-
tial pre-clinical efﬁcacy studies have indicated that the biological effects
of rVIIa-FP may be comparable to those of rFVIIa [6]. Clinical studies on
the efﬁcacy and safety of rVIIa-FP (CSL Behring GmbH) are underway in
the clinical trial programme PROLONG-7FP. Results of the ﬁrst-in-man
Phase I trial of rVIIa-FP have recently been reported and demonstrate
favourable safety and tolerability and a half-life of 6.1–9.7 hours, trans-
lating to a half-life extension of approximately 3- to 4-fold compared
with the commercially available rFVIIa product [7]. To inform thoseBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Representative radiochromatogram of rVIIa-FP illustrating its purity following
N­succinimidyl[2,3-3H]propionate (NSP) labelling. CPM, counts per minute.
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form shows any differences in tissue distribution compared with rFVIIa,
the present study was to designed to evaluate the biodistribution of
rVIIa-FP following a single intravenous administration in rodents, and
to compare it with the distribution of both rFVIIa and albumin [8].
Materials and Methods
Radiolabelling and Characterization of rVIIa-FP and rFVIIa
Tritium radiolabelling of rVIIa-FP (CSL Behring GmbH, Marburg,
Germany), or rFVIIa (NovoSeven®, Novo Nordisk Pharma GmbH,
Mainz, Germany) was conducted using the N­succinimidyl[2,3-3H]pro-
pionate (NSP; Quotient Bioresearch, Cardiff, UK), as described byMüller
[9]. Following puriﬁcation, size exclusion chromatography and ultravio-
let response conﬁrmed the speciﬁc radioactivity. Retention of biological
activity in [3H]-rVIIa-FP and [3H]-rFVIIa compared to unlabelled
material were evaluated using a Coaset chromogenic FVII assay kit
(Chromagenix, Milan, Italy).
Treatments
All treatments were prepared in phosphate-buffered saline. Male
Sprague–Dawley rats (Charles River, UK) (199–278 g) were adminis-
tered a single intravenous dose of 10 mg kg−1 [3H]-rVIIa-FP (n = 8)
or 1.6mg kg−1 [3H]-rFVIIa (n=4) as a slow bolus via the tail vein, pro-
viding a target dose of ~420 μCi kg−1. The protein dose of [3H]-rFVIIa
was chosen to match the rVIIa dose administered following a
10 mg kg−1 dose of [3H]-rVIIa-FP. Furthermore, the albumin dose
administered as part of [3H]-rVIIa-FP corresponds to the dose of [3H]-
albumin previously investigated by Herzog et al. [10]. All animal exper-
iments were subjected to the provisions of the UK Animals (Scientiﬁc
Procedures) Act 1986.
Plasma Analysis
Cardiac puncture blood samples (approximately 5–10 mL) were
taken under isoﬂuorane anaesthesia at 0.25, 1, 3, 8, 24, 72, 120 and
240 hours in the [3H]-rVIIa-FP group, and 0.25, 1, 3 and 24 hours in
the [3H]-rVIIa group (n = 1 per time point), collected into individual
heparinised containers, and processed to plasma. Pharmacokinetic
parameters were calculated usingMODFIT software (Version 4.0; Verity
Software House Inc.).
Excretion Balance
After dosing, animals selected for the ﬁnal autoradiography time
point were re-housed in glass metabolism cages for monitoring of
urine and faeces over 240 hours for [3H]-rVIIa-FP and 24 hours for
[3H]-rFVIIa. At the end of the observation period, the metabolism
cages were rinsed with water followed by methanol, and the washings
collected for quantitative radiochemical analysis.
Quantitative Whole-Body Autoradiography (QWBA)
QWBA was based on the technique of Ullberg et al. [11] at time
points up to 24 ([3H]-rFVIIa) or 240 ([3H]-rVIIa-FP) hours. Sagittal sec-
tions of the body were examined at up to ﬁve different levels: level 1,
exorbital lachrymal gland; level 2, intra-orbital lachrymal gland; level
3, harderian gland/adrenal gland; level 4, thyroid gland; and level 5,
brain and spinal cord. A series of 10 [3H]-blood standards comprising
control blood and [3H]-glycine (target range 10–10,000 nCi g−1) were
used for quantiﬁcation of tissue concentrations. Whole body and
blood standard sections were placed in close proximity to phosphor
bio-image plates at ambient temperature in the dark for 14 days. Radio-
activity biodistribution was visualized using a Fuji FLA-5100 bio-imageanalyser. The percentage total dose per tissue was calculated as de-
scribed previously [12]. Additionally, one hind limb from each animal
was sectioned for more detailed knee joint analysis.
Quantitative Radiochemical and Chromatographic Analysis
Liquid scintillation counting using Packard 2300TR liquid
scintillation analyser (PerkinElmer, Waltham, Massachusetts, USA)
was employed to evaluate the radioactivity concentrations (disintegra-
tions per minute) of the test product, plasma, urine, cage wash and
oxidized faeces after addition of Ultima Gold XR scintillation ﬂuid
(PerkinElmer). Faecal homogenates were ﬁrst combusted using a
Packard Sample Oxidizer 307 (PerkinElmer).
High-performance liquid chromatography (HPLC) (Agilent 1100
HPLC systemwith ultraviolet detection at 280 nm) using a Phenomenex
(Torrance, California, USA) BIOSEP SEC 2000 (rFVII-FP) or Phenomenex
Yarra 2000 (rFVIIa) size exclusion column (300× 7.8mm;mobile phase
100 mM sodium phosphate) allowed quantiﬁcation of radioactivity in
the test product solutions, plasma and urine samples, using an online
radiochemical detector (LabLogic, Shefﬁeld UK; β-Ram, model 3). If
samples contained low radioactivity levels, 6-second fractions of HPLC
eluent were collected, dried in a centrifugal evaporator (Genevac
HTX4, Ipswich, UK.), and counted on a Topcount Luminescence counter
(Perkin Elmer).
Results
Characterization of [3H]-rVIIa-FP and [3H]-rFVIIa Preparations
The radiochemical purity of all formulations was conﬁrmed; a
representative radiochromatogram of [3H]-rVIIa-FP is provided in
Fig. 1. Furthermore, 99% of biological activity was retained following
[3H]-NSP labelling of rVIIa-FP and rFVIIa (data not shown).
Analysis of Circulating Radioactivity and Pharmacokinetics
Plasma analysis showed the followingmean (range) dose and radio-
activity levels in each group: rVIIa-FP, 10.03mg kg−1 (9.01− 10.69) and
402.8 μCi kg−1 (362.2− 429.7); rFVIIa, 1.70 mg kg−1 (1.60− 1.80) and
444.2 μCi kg−1 (426.9–474.5).
3H
h i
−rVIIa−FP
The chromatographic proﬁle of [3H]-rVIIa-FP protein recovered in
plasma over time is shown in Fig. 2. Up to 8 hours after administration
Fig. 2. Plasma proﬁles of [3H]-rVIIa-FP at 8 (A) and 24 (B) hours post dosing. CPM, counts
per minute; LMW, low molecular weight.
Fig. 3.Concentration of radioactivity in plasma and pharmacokinetic parameters following
intravenous administration of [3H]-rVIIa-FP or [3H]-rFVIIa or [3H]-albumin to rats. Cmax,
maximum plasma concentration; T1/2, half-life.
Fig. 4. Radiochromatogram of rat urine following a single intravenous administration of
[3H]- rVIIa-FP (10 mg/kg) (A) or [3H]- rFVIIa (nominal 1.6 mg/kg) (B) to rats.
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activity corresponded to intact [3H]-rVIIa-FP, with a single peak at
7.0 minutes (Fig. 2A). From 24 hours onwards, additional peaks corre-
sponding to cleavage products such as albumin (7.4 minutes) and a
low-molecular-weight (LMW) component (12.7 minutes) appeared
(Fig. 2B). At this timepoint, 30% of the total radioactivity could still be
assigned to the intact [3H]-rVIIa-FP. At 240 hours, the radioactivity re-
lated to the intact protein had dropped below the limit of quantiﬁcation.
Pharmacokinetic analysis showed that rVIIa-FP was cleared slowly
with a terminal plasma half-life of 20.8 hours and a clearance rate of
1.96 mLh−1. The Tmax was reached at the ﬁrst time point measured
(0.25 hours); Cmax of rVIIa-FP was 136.7 μg Eq g−1 and the AUC0-∞
was 1,286.6 μg Eq∙h g−1 (Fig. 3).
3H
h i
−rFVII
Following administration of rFVIIa, plasma radioactivity mainly
represented the intact protein up to 3 hours (78-88%), with the peak
at 7.4 minutes. However, a LMW component was identiﬁed as early as
0.25 hours post-dose and radioactivity levels assignable to intact
protein have dropped to 27% by 24 hours. rFVIIa had a much shorter
half-life of 5.0 hours and was cleared much faster (5.65 mL h−1) than
rVIIa-FP. Tmax of rFVIIa was 0.25 hours; Cmax was 15.8 μg Eq g−1 and
the AUC0-∞ was 69.9 μg Eq∙h g−1(Fig. 3).
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All radioactivity detected in urine by HPLC appeared to elute at a
retention time associated with a non-volatile LMW component (Fig. 4).
3H
h i
−rVIIa−FP
Urinary excretion accounted for 74% of the [3H]-rVIIa-FP dose elim-
inated within 240 hours, while faecal elimination accounted for 17%
(Table 1). Overall, 92% of the radioactivity administered was excreted
within 240 hours (Table 1).
3H
h i
−rFVII
Similarly, rFVIIa was primarily excreted in the urine (72% within
24 hours), with 2% eliminated via the faecal route and 23% collected in
the cage washings (Table 1).
Tissue Distribution
Tissue Concentration and Kinetics
3H
h i
−rVIIa−FP
High concentrations of [3H]-rVIIa-FP radioactivity were distributed
to kidney (particularly the medulla and cortex regions), bone endoste-
um, spleen, bone marrow, lung, liver, myocardium and periodontal
membrane (Figs. 5 and 6). Peak levels of [3H]-rVIIa-FP radioactivity
were seen in most tissues between 0.25 to 8 hours post-dose, and
declined thereafter (Figs. 5 and 6). At 8 hours post-dose, high con-
centrations remained in the kidney (1,750.0 nCi g−1) and spleen
(1,210.0 nCi g−1), with the highest radioactive concentration at
this time point in the kidneymedulla (2,480.0 nCi g−1). When calculat-
ed as a percentage of the dose per tissue, the highest total dose at
0.25 hours was observed in the muscle followed by the liver, kidney,
small intestinal mucosa and lung (Fig. 7A). After 24 hours, the highest
percentage of the total dose was seen in the muscle followed by the
skin and bone (Fig. 7A).
3H
h i
−rFVIIa
High concentrations of [3H]-rFVIIa were detected in the liver, bone
endosteum, kidney, lung, bone marrow, spleen and myocardium
(Figs. 5 and 7B). Peak levels were generally seen at 0.25 hours (liver
4,850.0 nCi g−1; lung 2,410.0 nCi g−1; bone marrow 1,870.0 nCi g−1)
or 1 hour (kidney whole 4,060.0 nCi g−1; spleen 1,540.0 nCi g−1)Table 1
Summary of urinary, faecal and cage recoveries (expressed as % of overall radioactivity
administered).
Sample Time (h) [3H]-rVIIa-FP [3H]-rFVIIa [3H]-albumin
Urine 0 − 8 15.8 54.9 10.7
8 − 24 26.0 17.5 36.8
24 − 48 16.9 − 28.7
48 − 240 15.3 − 37.2
Subtotal 74.0 72.4 113.4
Faeces 0 − 24 3.7 2.1 3.7
24 − 48 3.5 − 2.0
48 − 240 9.9 − 6.9
Subtotal 17.2 2.1 12.5
Cage Subtotal 0.8 22.9 0.7
Total∑ 91.9 97.4 126.7
Abbreviations: rFVIIa, recombinant factor VIIa; rVIIa-FP, recombinant fusion protein
linking coagulation factor VIIa with albumin.post-dose. When calculated as a percentage of the dose per tissue, at
0.25 hours, the highest total dose was observed in the liver, followed
by the muscle, skin, and kidney (Fig. 7B). After 24 hours, the highest
percentage of the total radioactive dose was seen in the muscle, follow-
ed by liver, skin and bone (Fig. 7B). Concentrations of [3H]-rFVIIa
declined rapidly, to levels close to or below the limit of quantiﬁcation
by 24 hours. When considering the tissue concentrations, it should be
noted that the total radioactive dose administered was higher for rFVIIa
than rVIIa-FP (444.2 vs. 402.8 μCi kg−1).
Knee joint distribution
3H
h i
−rVIIa−FP
Detailed analysis of the knee joint showed high concentrations of
radioactivity in the zone of calciﬁed cartilage within the growth plate
region, the endosteum (inner membranous lining) and the periosteum
(outer membranous lining) (Fig. 8), peaking between 0.25− 8 hours
post-dose (endosteum 1,410 nCi g−1). Epiphyseal plate, meniscus and
compact bone in the femur, ﬁbula or tibia contained low radioactivity
throughout. Radioactivity in the synovial space was greatest at
3 hours (567.0 nCi g−1). Calciﬁed cartilage, bonemarrow and epiphyse-
al plate retained detectable radioactivity up to 240 hours post-dosing,
although the highest level at this time point was in the endosteum
(189.0 nCi g−1).
3H
h i
−rFVIIa
Within the knee joint, similar to rVIIa-FP, the highest concentration
of [3H]-rFVIIa was observed in the calciﬁed cartilage of the growth
plate (peak 8,320.0 nCi g−1 at 3 hours), with low levels in the compact
bone in the femur, ﬁbula and tibia. Synovial space concentration peaked
at 0.25 hours post-dose, decreasing to undetectable levels by 24 hours
post-dose. At 24 hours, the highest level of radioactivity was seen in
the calciﬁed cartilage (2,380.0 nCi g−1) and endosteum (754 nCi g−1)
(Fig. 8).
Discussion
Biodistribution data from this pre-clinical study show that rVIIa-FP
penetrates well into many tissues, predominantly kidney, bone
endosteum, bone marrow, spleen, muscles, liver and skin. Within
0.25 hours, rVIIa-FP is already present in diverse tissues. Muscles and
liver received the highest percentage of the total dose administered,
while kidney and bone endosteumdisplayed the highest concentrations
of radioactivity; both for [3H]-rVIIa-FP and [3H]-rFVIIa. The similar
biodistribution proﬁle between rVIIa-FP and rFVIIa is valuable knowl-
edge for clinical practice. Importantly, our ﬁndings regarding tissue
penetration of rFVIIa agree with previous reports [13–15]. For example,
a previous rat biodistribution study showed that 125I-rFVIIa was associ-
atedwith lung, liver, kidney and spleen at 30min post-dose [13–15]. No
evidence of kidney or liver accumulation was found, as levels declined
during the study.
In the knee joint, rVIIa-FPwasmainly found in the calciﬁed cartilage,
endosteum and periosteum. Furthermore, the longest retention of
rVIIa-FP was seen in bone tissue. This is an important feature of
rVIIa-FP because of the tendency for recurrent bleeds, particularly
in the knee and ankle joints, among patients with severe/moderate
haemophilia; thus warranting high concentrations of clotting factor
concentrate in these susceptible regions. Penetration and accumulation
of rFVII in the bone compartment have previously been demonstrated
[14–16]. However, an interesting difference was noted in the retention
of the two forms of the coagulation factor in bone. While rFVIIa had
declined to almost undetectable levels by 24 hours post-dose, rVIIa-FP
Fig. 5.Quantitativewhole-body autoradiography images obtained at 0.25–240 hours following a single intravenous administration of [3H]-rVIIa-FP to rats: left panels (Section levels 2/3);
right panels (Section levels 4/5).
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differs from an earlier study in which a signiﬁcant amount of rFVIIa
was present in the zone of calciﬁed cartilage up to one week post-
administration [15]. The differences observedmay be attributable to dif-
ferences in the resolution of the analysis method used, i.e. QWBA versus
microscopical assessment of tissue slides following immunohistochem-
ical staining. The present studymay therefore under-estimate the tissueconcentrations of rVIIa-FP and rFVIIa present. Effective prevention and
management of joint bleeding in patients with haemophilia is of the
utmost importance [17]. Recurrent intra-articular bleeding can lead to
synovitis − inﬂammation and proliferation of the synovium − and
contribute to end-stage degeneration− haemophilic arthropathy. The
associated pain and restriction of movement is distressing for patients
and severely affects their quality of life. Early, effective treatment is,
Fig. 6. Quantitative whole-body autoradiography images obtained at 0.25 (left panels) and 24 (right panels) hours following a single intravenous administration of [3H]-rVIIa-FP or
[3H]-rFVIIa to rats.
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studies will be required to understand, in more detail, the mechanism
and role of coagulation factor distribution to the mineralized bone re-
gion, and also the potential to exploit the long retention of rVIIa-FP levels
in the bone and muscle for prophylaxis in the clinical setting. Follow-upFig. 7. Tissue concentration of radioactivity at 0.25 and 24 hours following instudies would also be required to conﬁrm the presence of the rVIIa-FP
and rFVIIa proteins and of FVIIa activity within the tissues identiﬁed
based on the quantitation of tissue radioactivity in this study.
Although the spatial pattern of distribution across tissues is similar
between rFVIIa and rVIIa-FP, the temporal pattern of their movementtravenous administration of [3H]-rVIIa-FP (A) or [3H]-rFVIIa (B) to rats.
Fig. 8. Quantitative whole-body autoradiography images of the knee joint tissue obtained at 0.25–120 hours after [3H]-rVIIa-FP (A) and 0.25–24 hours after [3H]-rFVIIa (B) dosing.
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rFVIIa than with rVIIa-FP treatment. This ﬁnding can be explained by
the markedly higher plasma concentrations of rVIIa-FP observed at the
early time points. Pre-clinical efﬁcacy studies conﬁrm that this differ-
ence in plasma concentrations does not impact the onset of the pharma-
cological activity of the two products [18].While this difference in tissue
concentrations diminishes intermittently over time, longer time points
reveal some interesting variances. Tissue retention of [3H]-rVIIa-FP
was longer compared with [3H]-rFVIIa. For example, [3H]-rVIIa-FP was
retained in bone up to 240 hours post-dose, while the latest detected
signal in rFVIIa-treated animals was already close to the lower limit of
quantiﬁcation by 24 hours. The mechanism underlying the extended
distribution of rVIIa-FP in tissues has not been studied herein; however,
it can be postulated to involve the albumin fusion partner and neonatal
Fc-receptor-mediated recycling leading to prolonged availability, or
increased size, enabling it to avoid rapid clearance [19]. The prolonged
tissue retention of [3H]-rVIIa-FP is also reﬂected in the pharmacokinetic
ﬁndings.
Pharmacokinetic analyses conﬁrmed that rVIIa-FP was detectable in
plasma up to 120 hours post-dosing, with a Tmax at 0.25 hours and T½ of
20.8 hours which is longer compared to the T½ reported by Weimer
et al. (2008) and Zollner et al. (2014). This may be explained by the lim-
ited number of replicates included in the current study (n= 1 per time
point), the larger protein doses administered and/or the difference in
analysismethod used [4,6]. From the 24-hour time point onwards, albu-
min and a LMW component comprised the main degradation products
of rVIIa-FP. In contrast, rFVIIa already showed low plasma levels by
24 hours post-dose and a LMW component was already detectable
0.25 hours following administration of rFVIIa. Similarly, in a previous
examination of the distribution of 125I-rFVIIa, tissue levels of the coagu-
lation factor declined to low levels by 24 hours [14]. Furthermore, while
urinary excretion, in the form of a non-volatile LMW component, pro-
vided the principal pathway of elimination for rVIIa-FP, rFVIIa and
albumin-associated radioactivity, the excretion time course differed,
with accelerated clearance of [3H]-rFVIIa compared with [3H]­rVIIa-FP.
Similar to [3H]­rIX-FP [10]. intact rVIIa-FP or rFVIIa proteinswere absent
in urine, suggesting endocytosis of the proteins and subsequentdegradation by lysosomal proteases, as described for other proteins
[20,21].
Overall, exposure to rVIIa-FP was approximately 18-fold higher,
with a four-fold longer terminal half-life compared to rFVIIa which
in turn correlates well with the published literature [4,6]. These phar-
macokinetic studies in rats clearly demonstrate that albumin fusion
translates into extended availability of the coagulation factor within
the circulation. Furthermore, these ﬁndings concur with previous
pre-clinical pharmacokinetic comparisons of these two forms of the
coagulation factor [22].
This pre-clinical study shows that recombinant fusion protein
linking coagulation factor VIIa with albumin, rVIIa-FP, exhibits equiva-
lent biodistribution to rFVIIa. However, rVIIa-FP clearly distinguishes it-
self by a prolonged presence in plasma and tissues − up to 10 times
longer than rFVIIa in some tissues, including muscle tissue and bone,
suggesting that the rVIIa moiety is directing rVIIa-FP’s tissue distribu-
tion, while the albumin moiety is responsible for the prolonged plasma
and tissue retention. As shownbyHerzog et al. [10], [3H]-albumin,when
administered at doses correlating to the albumin portion of a 10 mg/kg
dose of rVIIa-FP, was detectable in plasma up to 240 hours post-dosing.
This ﬁnding is similar to the long plasma retention time observed
for [3H]-rVIIa-FP in the present study. However, in contrast to
[3H]-rVIIa-FP and also [3H]-rIX-FP, [3H]-albumin elicited a distinct tissue
distribution pattern. Overall, these ﬁndings further conﬁrm the half-life
extension of [3H]-rVIIa-FP provided by the novel design involving albu-
min fusion and aﬂexible linker sequence. The extended pharmacokinet-
ics and biodistribution of rVIIa-FP are expected to enable a reduced
dosing frequency and aid with increased therapeutic compliance and
convenience in patients with bleeding disorders.
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